These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 22886470)
41. Tumour necrosis factor α blockers are more effective than methotrexate in the inhibition of radiographic joint damage progression among patients with psoriatic arthritis. Eder L; Thavaneswaran A; Chandran V; Gladman DD Ann Rheum Dis; 2014 Jun; 73(6):1007-11. PubMed ID: 23619157 [TBL] [Abstract][Full Text] [Related]
42. Spotlight on etanercept in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis. Culy CR; Keating GM BioDrugs; 2003; 17(2):139-45. PubMed ID: 12641492 [TBL] [Abstract][Full Text] [Related]
43. Recurrent infections in a patient with psoriatic arthritis and hypogammaglobulinemia, treated with conventional and biologic disease-modifying anti-rheumatic drugs-a primary or secondary entity? Więsik-Szewczyk E; Kucharczyk A; Świerkocka K; Rutkowska E; Jahnz-Różyk K Clin Rheumatol; 2017 Jul; 36(7):1677-1681. PubMed ID: 28488125 [TBL] [Abstract][Full Text] [Related]
44. [Psoriasis and psoriatic rheumatism: effectiveness of etanercept for cutaneous and joint lesions]. Paul C; Solignac M Ann Dermatol Venereol; 2010 Apr; 137(4 Suppl):13-5. PubMed ID: 20510165 [No Abstract] [Full Text] [Related]
45. [Therapy of rheumatoid arthritis with etanercept]. Lamprecht P; Nitschmann S Internist (Berl); 2009 May; 50(5):633-4. PubMed ID: 19350212 [No Abstract] [Full Text] [Related]
46. Psoriatic onychopachydermoperiostitis: improvement with etanercept. Dans M; Hivnor C; van Voorhees AS Br J Dermatol; 2005 Oct; 153(4):858-9. PubMed ID: 16181482 [No Abstract] [Full Text] [Related]
47. Secondary addition of methotrexate to partial responders to etanercept alone is effective in severe rheumatoid arthritis. Cohen JD; Zaltni S; Kaiser MJ; Bozonnat MC; Jorgensen C; Daurès JP; Sany J Ann Rheum Dis; 2004 Feb; 63(2):209-10. PubMed ID: 14722213 [No Abstract] [Full Text] [Related]
48. Etanercept for psoriasis and psoriatic arthritis in a patient with Charcot-Marie-Tooth disease. Guarneri C; Russo M; Mazzeo A; Cannavò SP Ann Pharmacother; 2014 Apr; 48(4):550-1. PubMed ID: 24658637 [No Abstract] [Full Text] [Related]
49. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study. Esposito M; Giunta A; Mazzotta A; Zangrilli A; Babino G; Bavetta M; Perricone R; Chimenti S; Chimenti MS Dermatology; 2012; 225(4):312-9. PubMed ID: 23295383 [TBL] [Abstract][Full Text] [Related]
50. Baseline characteristics and patient reported outcome data of patients prescribed etanercept: web-based and telephone evaluation. Wade AG; Crawford GM; Pumford N; Koscielny V; Maycock S; McConnachie A BMC Med Res Methodol; 2011 Jun; 11():91. PubMed ID: 21672203 [TBL] [Abstract][Full Text] [Related]
51. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population. Schabert VF; Watson C; Joseph GJ; Iversen P; Burudpakdee C; Harrison DJ J Manag Care Pharm; 2013 Oct; 19(8):621-30. PubMed ID: 24074008 [TBL] [Abstract][Full Text] [Related]
52. Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept. Kamarashev J; Lor P; Forster A; Heinzerling L; Burg G; Nestle FO Dermatology; 2002; 205(2):213-6. PubMed ID: 12218252 [TBL] [Abstract][Full Text] [Related]
53. Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment. Strand V; Sharp V; Koenig AS; Park G; Shi Y; Wang B; Zack DJ; Fiorentino D Ann Rheum Dis; 2012 Jul; 71(7):1143-50. PubMed ID: 22258482 [TBL] [Abstract][Full Text] [Related]
54. Treatment of psoriatic arthritis with etanercept, a tumour necrosis factor antagonist. Wong VK; Lebwohl MG Expert Opin Biol Ther; 2005 Nov; 5(11):1505-13. PubMed ID: 16255653 [TBL] [Abstract][Full Text] [Related]
55. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Woolacott N; Bravo Vergel Y; Hawkins N; Kainth A; Khadjesari Z; Misso K; Light K; Asseburg C; Palmer S; Claxton K; Bruce I; Sculpher M; Riemsma R Health Technol Assess; 2006 Sep; 10(31):iii-iv, xiii-xvi, 1-239. PubMed ID: 16948890 [TBL] [Abstract][Full Text] [Related]
56. Trial of etanercept and methotrexate with radiographic and patient outcomes two-year clinical and radiographic results: Comment on the article by van der Heijde et al. Yazici Y; Yazici H Arthritis Rheum; 2006 Sep; 54(9):3061-2. PubMed ID: 16948140 [No Abstract] [Full Text] [Related]
57. Visceral leishmaniasis in an infant following a holiday trip to Spain. Trück J; Rampton C; Kelly SJ; Kelly D BMJ Case Rep; 2015 Apr; 2015():. PubMed ID: 25920739 [TBL] [Abstract][Full Text] [Related]